An audit of the efficacy of Botulinum toxin for myofascial pain

We undertook a prospective audit of the efficacy of botox use for myofascial pain in the face. Inclusion criteria were age over 16, diagnosis of myofascial pain only (ie no joint component), failed conservative measures, and attended follow upat 3 and 6 months. Outcome measures were pain score (recorded on a visual analogue pain chart) and maximal interincisal opening (MIO). We used an evidence based gold standard of a 50% reduction in pain score and 17% increase in MIO.The first cycle included eight patients, patents were given25 units of botulinum toxin into the masseter muscles, with a further 50u.

Source: The British Journal of Oral and Maxillofacial Surgery - November 30, 2016 Category: ENT & OMF Authors: Stephanie Milne, Lachlan Carter, Tamsin Cooper Tags: P173 Source Type: research